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ABSTRACT
Background: Recent evidence suggests that distinction
of subsets of rheumatoid arthritis (RA) depending on anti-
cyclic citrullinated peptide antibody (anti-CCP) status may
be helpful in distinguishing distinct aetiopathologies and in
predicting the course of disease. HLA-DRB1 shared
epitope (SE) and peptidylarginine deiminase type 4
(PADI4) genotype, both of which have been implicated in
anti-CCP generation, are assumed to be associated with
RA.
Objectives: To elucidate whether PADI4 affects the
clinical characteristics of RA, and whether it would
modulate the effect of anti-CCPs on clinical course. The
combined effect of SE and PADI4 on autoantibody profile
was also analysed.
Methods: 373 patients with RA were studied. SE,
padi4_94C.T, rheumatoid factor, anti-CCPs and anti-
nuclear antibodies (ANAs) were determined. Disease
severity was characterised by cumulative therapy
intensity classified into ordinal categories (CTI-1 to CTI-3)
and by Steinbrocker score.
Results: CTI was significantly associated with disease
duration, erosive disease, disease activity score (DAS) 28
and anti-CCPs. The association of anti-CCPs with CTI was
considerably influenced by padi4_94C.T genotype (C/C:
ORadj = 0.93, padj = 0.92; C/T: ORadj = 2.92,
padj = 0.093; T/T: ORadj = 15.3, padj = 0.002). Carriage of
padi4_94T exhibited a significant trend towards higher
Steinbrocker scores in univariate and multivariate
analyses. An association of padi4_94C.T with ANAs
was observed, with noteworthy differences depending on
SE status (SE2: ORadj = 6.20, padj,0.04; SE+:
ORadj = 0.36, padj = 0.02) and significant heterogeneity
between the two SE strata (p = 0.006).
Conclusions: PADI4 genotype in combination with anti-
CCPs and SE modulates clinical and serological char-
acteristics of RA.
Rheumatoid arthritis (RA) is a common chronic
autoimmune disease of unknown aetiology.1 A
central challenge in clinical practice is the identi-
fication of patients who need more intensive
treatment at an early stage, as many patients
develop joint damage during the first few months
after disease onset.2 3 Rheumatoid factor (RF) and/
or anti-citrullinated protein antibodies (ACPAs)
have been implicated to be associated with more
severe joint destruction and a more aggressive
disease course.1 4 5 The major function of HLA-
DRB1 shared epitope (SE) in the pathogenesis of
RA is thought to primarily consist of giving the
appropriate immunological context to respond to
environmental challenges with production of
ACPAs, which themselves influence disease.6–9
The association of SE with ACPA-positive RA
and its influence on ACPA concentration is well
established.5 Another genetic trait that presumably
influences susceptibility to RA is the peptidyl-
arginine deiminase type 4 (PADI4, MIM: 605347)
genotype reflected by padi4_94C.T (rs2240340).10–12
PADI4 post-translationally converts peptide-bound
arginine residues into citrulline, and this process
generates citrullinated epitopes, which are the
essential targets of the RA-specific ACPAs.5
In this retrospective study, we analysed the
association of padi4_94C.T and anti-citrullinated
peptide antibodies (anti-CCPs), a prime example of
ACPAs, with disease severity as reflected by
cumulative therapy intensity (CTI), which was a
priori classified into three ordinal categories.13
Erosive joint status assessed by Steinbrocker score
was used as an additional indicator of disease
severity. To reveal possible modulating properties
of the PADI4 genotype on the effect of anti-CCPs
on disease severity, we stratified analyses by
padi4_94C.T. Finally, we analysed the interactive
effect of SE and PADI4 genotype on the auto-
antibody profile.
METHODS
Study population and clinical data
In this study, 373 consecutive patients with RA
presenting for regular visits were enrolled from the
Department of Rheumatology and Clinical
Immunology, Charite´ Berlin. All patients fulfilled
the American College of Rheumatology criteria for
the classification of RA.14 The patients are under
continuous medical attendance in our outpatient
unit. Individual therapy courses of all enrolled
patients were recorded. The CTI was a priori
classified into three ordinal categories (CTI-1:
methylprednisone, hydroxychloroquine, sulfasala-
zine; CTI-2: methotrexate, gold, leflunomide,
ciclosporin A, azathioprine; CTI-3: cyclophospha-
mide, tumour necrosis factor a blockers). Patients
were classified on the basis of the antirheumatic
drug corresponding to the highest CTI category
they had ever received. This classification is a local
adaptation of an approach described previously for
the assessment of RA severity.13 Radiographic data
from the time of enrolment were available in 290
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cases. Classification into non-erosive (Steinbrocker score (I)
and erosive (Steinbrocker scores II–IV) disease was performed.15
The genotype frequencies of padi4_94C.T in a control group
consisting of healthy people and non-RA patients from our
geographic region were determined in 282 consecutive caucasian
blood donors and 335 consecutive patients with no history of
autoimmune diseases presenting at our clinic for thrombophilia
work-up.16
The study was approved by the local ethics committee. All
participants were included in the study after they had provided
informed consent.
Autoantibody detection
Anti-CCP IgG antibodies were quantified in 346 patients at the
time of enrolment with a second-generation ELISA using the
Immunoscan RA kit (Euro-Diagnostica, Dahlewitz, Germany).
A cut-off value of 25 arbitrary units/ml was used.
ANAs were determined in 354 patients using an indirect
immunofluorescence assay on HEp-2 cells with an IgG-specific
secondary antibody (Generic Assays, Dahlewitz, Germany).
Patients with a titre of >320 were considered ANA positive.
RFs were quantified in 359 patients using an ELISA-based
IgM-specific technique and a cut-off value of 24 IU/ml (DLD
Diagnostika, Hamburg, Germany).
Genotyping of PADI4 and SE
PADI4 genotypes were discriminated for all patients and
controls by padi4_94C.T (rs2240340) using allele-specific
primer pairs. Specificities of the primer pairs were evaluated
on 30 sequenced DNA samples.17 18
SE was defined by HLA-DRB1 alleles with the following
constellation at the corresponding DRb1 chain residues: 67Leu–
69Glu–71Lys or Arg–74Ala–86Gly or Val.19 SE status was
available for 215 patients with RA and 282 healthy controls.
High-resolution HLA-DRB1 typing was performed using stan-
dard techniques (Dynal, Oslo, Norway; GenoVision, Vienna,
Austria; Protrans, Ketsch, Germany).18
Statistical analysis
For univariate analyses, odds ratios (ORs) and exact 95% CIs
were calculated. For stratified univariate analyses, Breslow and
Day’s (BD) x2 test of homogeneity was used to test whether an
association differed significantly across the two strata. For
calculations on the effect of allele dose of padi4_94C.T or SE
genotype, the corresponding wild-type was used as the reference
group, and a test for linear trend of the log odds (trend test) was
included.
For multivariate analyses, ORs and 95% CIs were calculated
by logistic regression analyses with adjustment for sex, duration
of disease, disease activity score (DAS)28 and erosive joint
status or CTI. For analyses on autoantibody profile, sex,
duration of disease, DAS28, CTI and presence of RFs, anti-
CCPs and ANAs were included. Depending on the variable used
for stratification (SE or padi4_94C.T), the logistic regression
model contained padi4_94C.T or SE genotype, respectively.
The Wald test was used to test whether an association differed
significantly across the two stratified logistic regression models.
The comparisons of autoantibody concentrations between
PADI4 and SE genotypes were performed by Mann–Whitney
U test or, in the case of testing for allele-dose-dependency, by
the Cuzick non-parametric test for trend. All statistical analyses
were performed using Stata Statistical Software for Macintosh,
release 10.0.
RESULTS
Characteristics of the study population
Table 1 gives the characteristics of the RA population.
The controls consisted of healthy individuals and non-RA
patients. In healthy individuals, 62.1% were carriers of
padi4_94T (1 copy, 47.9%; 2 copies, 14.2%). SE was present in
35.8% of healthy controls (1 copy, 28.7%; 2 copies, 7.1%). In the
non-RA patients, 61.8% were carriers of padi4_94T (1 copy,
47.2%; 2 copies, 14.6%). There was no heterogeneity in the
distribution of PADI4 genotypes between either part of the
control group (p = 0.98).
PADI4 genotype and RA
Carriage of padi4_94T was associated with susceptibility to RA
(OR = 1.38, p = 0.02). This association was allele-dose-dependent
(trend test, p = 0.005; 1 copy: OR = 1.28, p = 0.09; 2 copies:
OR = 1.70, p = 0.006). As the padi4_94C.T genotype distribu-
tion in our patients with RA was dependent on CTI and
Steinbrocker score, we tested whether association of
padi4_94C.T with susceptibility to RA would be restricted to
patients with more severe disease. In fact, whereas there were no
significant differences in PADI4 genotype distributions in patients
with CTI-1 or Steinbrocker scores ,II compared with controls
(trend test, p = 0.82 and p = 0.24, respectively), in patients with
higher disease severity, ie, CTI-2/3 (CTI-2/3 versus controls: trend
test, p = 0.0003; 1 copy: OR = 1.47, p = 0.03; 2 copies: OR = 2.26,
p = 0.0002) or Steinbrocker score >II (Steinbrocker score >II
versus controls: trend test, p = 0.0005; 1 copy: OR = 1.29,
p = 0.20; 2 copies: OR = 2.34, p = 0.0003), padi4_94C.T was
significantly associated with RA.
Factors influencing CTI
In univariate and multivariate analyses, duration of disease,
presence of erosive disease, anti-CCP status and DAS28 were
significantly associated with CTI (CTI-2/3 versus CTI-1)
(table 2). An association of padi4_94C.T carrier status with
CTI could be demonstrated only in univariate analysis (table 2).
Table 1 Characteristics of the study population (n = 373)
Characteristic Patients with RA
Age (years) 51 (38–61)
Female 76.1
Disease duration (years) 5 (1–11.3)
Rheumatoid factor (>25 IU/ml) 75.8
Titre (IU/ml) 97 (25–277)
Anti-CCPs (.25 AU/ml) 61.3
Titre (AU/ml) 91 (1–568)
Antinuclear antibodies (>320) 29.4
Titre 80 (80–320)
Shared epitope 49.3 (SE/se), 13.5 (SE/SE)
padi4_94C.T 49.3 (C/T), 19.8 (T/T)
Steinbrocker score 36.2 ( I), 41.4 (II), 14.1 (III), 8.3 (IV)
Disease activity score 28 5.0 (4.03–6.19)
,3.2 15.7
3.2–5.1 32.2
.5.1 52.2
CTI 38.6 (CTI-1), 46.9 (CTI-2), 14.5 (CTI-3)
Values are either percentage or median (interquartile range).
Anti-CCP, anti-cyclic citrullinated peptide; CTI, cumulative therapy intensity; SE/se, 1
copy of shared epitope; SE/SE, 2 copies of shared epitope; C/T, padi4_94C/T (variant
heterozygous); T/T, padi4_94T/T (variant homozygous).
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The presence of neither RFs, ANAs nor SEs directly influenced
CTI. With respect to the relation between anti-CCPs and CTI, a
diverging effect was found after stratification for padi4_94C.T,
with restriction of the association of anti-CCPs with CTI to the
padi4_94T positive stratum (OR = 2.00, p = 0.01) (table 2). The
difference in the effect of anti-CCPs on CTI between the two
padi4_94C.T strata in univariate analysis did not reach
statistical significance (BD x2 test of homogeneity, p = 0.21).
However, in strata defined by padi4_94C, ie, carriage of at least
one padi4_94C (wild-type) allele, and padi4_94T/T (two
padi4_94T copies), anti-CCPs were significantly associated with
CTI only in the padi4_94T/T stratum (OR = 5.2, p = 0.002)
with significant heterogeneity between the two strata (BD x2
test of homogeneity, p = 0.02) (table 2). Logistic regression
analyses confirmed that anti-CCPs were independently asso-
ciated with CTI only in padi4_94T-positive patients
(padi4_94T: ORadj = 3.46, padj = 0.007; padi4_94T/T:
ORadj = 15.3, padj = 0.002) (table 2).
On comparison of padi4_94T carrier status in all CTI
categories, among anti-CCP-positive patients the frequency of
padi4_94T carriers increased significantly from 63.0% in CTI-1
to 73.8% and 88.9% for CTI-2 and CTI-3, respectively (trend
test, p = 0.004; CTI-2: OR = 1.65, p = 0.13; CTI-3: OR = 4.70,
p = 0.005 (reference: CTI-1)) (fig 1A). In anti-CCP-negative
patients, the frequency of padi4_94T carriers was essentially the
same as that of the control group for all CTI categories (CTI-1:
63.5%; CTI-2: 67.2%; CTI-3: 61.5%) (fig 1B).
Factors influencing erosive joint status
Duration of disease (p,1029, padj,0.0001) and CTI (OR = 4.50,
p,1028; ORadj = 2.05, padj = 0.03) influenced directly erosive
joint status (Steinbrocker score >II) in univariate and multi-
variate analyses. The presence of neither anti-CCPs (OR = 1.45,
p = 0.15), RFs, ANAs, SE, DAS28, nor padi4_94T were
significantly associated with the presence of erosive disease
(Steinbrocker score >II). When padi4_94T carrier status was
analysed in ordinal categories defined by Steinbrocker scores, a
trend towards higher padi4_94T carrier frequencies with
increasing Steinbrocker scores could be detected in our study
population (trend test, p = 0.06 (reference: Steinbrocker score
(I) and p,0.004 (reference: controls)) (fig 2A). When carriage
of two padi4_94T copies (padi4_94T/T) was considered, the
increasing frequency of carriers with increasing Steinbrocker
scores was even more pronounced (trend test, p,0.003
(reference: Steinbrocker score (I) and p,1025 (reference:
controls)) (fig 2B). After adjustment for possible confounding
factors (sex, age, duration of disease, DAS28, CTI, serological
status), the trend for higher padi4_94T and padi4_94T/T
frequencies with increasing Steinbrocker scores continued to
be detectable at comparable statistical significance levels
(padi4_94T: padj,0.004; padi4_94T/T: padj = 0.008 (reference:
Steinbrocker score (I)) (fig 2).
Factors influencing autoantibody profile
The combined influence of SE and padi4_94C.T on autoanti-
body profile was analysed in 215 patients, who had been
completely characterised for both genotypes. Presence of anti-
CCPs and the anti-CCP concentration were clearly associated
with the presence of SE (OR = 2.93; p = 0.0002, Mann–Whitney
U test: p,0.0001) and number of SE alleles (trend test:
p = 0.0001). Presence of anti-CCPs was significantly influenced
by neither carriage of padi4_94T (OR = 1.43, p = 0.13) nor
padi4_94T allele dose (1 copy: OR = 1.32, p = 0.27; 2 copies:
OR = 1.77, p = 0.08; trend test: p = 0.07 (reference: padi4_94C/C)).
In univariate analyses, no further association between presence
of anti-CCPs, RFs or ANAs and a single genotype (SE or
Table 2 Factors influencing disease severity as reflected by cumulative
therapy intensity (CTI-2/3 versus CTI-1)
OR (p value) Adjusted OR (p value)
Duration of disease (quartiles) (n = 356) ,10226 ,0.001
Erosive disease (n = 290) 4.50 (,1028) 2.14 (0.02)
Disease activity score (DAS) 28
(n = 370)
(,1025) (0.003)
,3.2 (n = 58) 1 (referent) 1 (referent)
3.2–5.1 (n = 119) 0.46 (0.05) 0.29 (,0.04)
.5.1 (n = 193) 0.21 (1025) 0.18 (0.003)
Anti-CCP (n = 346) 1.69 (,0.02) 2.32 (,0.02)
padi4_94C/C (n = 105) 1.10 (0.81) 0.93 (0.92)
padi4_94T (n = 241) 2.00 (0.01) 3.46 (0.007)
padi4_94C (n = 276) 1.31 (0.28)* 1.78 (0.18){
padi4_94T/T (n = 70) 5.20 (0.002)* 15.3 (0.002){
padi4_94T (n = 373) 1.57 (,0.05) 1.22 (0.57)
Odds ratios (ORs) and p values of univariate and multivariate analyses (adjusted for
sex, age, duration of disease, DAS28 and erosive joint status if applicable) are given.
Numbers of patients are indicated.
*BD x2 test of homogeneity: p = 0.02.
{Wald test: p,0.02.
Figure 1 Influence of padi4_94C.T on cumulative therapy intensity
(CTI) dependent on the antibody to cyclic citrullinated peptide (anti-CCP)
status. Carrier frequencies of padi4_94T in controls and in (A) anti-CCP-
positive and (B) anti-CCP-negative patients with rheumatoid arthritis
ordinally categorised by CTI (CTI-1 to CTI-3) are shown.
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padi4_94C.T) could be identified. However, after stratification for
SE, the influence of padi4_94C.T genotype on autoantibody
profile was notable (fig 3). In univariate and multivariate analyses,
significant heterogeneity existed between SE-positive and SE-
negative patients with respect to association of padi4_94C.T
genotype with ANAs (test of homogeneity, p,0.01 and
padj = 0.006, respectively), with positive association in the SE-
negative stratum and negative association in the SE-positive
stratum (table 3).
The same phenomenon was observed when padi4_94T allele
dose was considered. In SE-positive patients, the number of
padi4_94T alleles was negatively associated with ANAs (trend
test, p,0.02), and in SE-negative patients there was a positive
association (trend test, p,0.03) when padi4_94C/C was used as
the reference group (fig 3). The heterogeneity of this allele-dose-
dependent effect between the two SE strata was highly
significant in univariate (p = 0.001) and multivariate
(padj = 0.0002) analyses (table 3).
DISCUSSION
The results of this study suggest that the PADI4 genotype
critically modulates the effect of anti-CCPs on clinical
characteristics of RA. The PADI4 genotype itself appears to
influence joint destruction. Interactively, PADI4 genotype and
SE influence the autoantibody profile of RA. Hence, it could be
hypothesised that information on the two genetic traits
characterise different RA subsets with distinct aetiopathogen-
eses. Finally, an association of padi4_94C.T with susceptibility
for RA was confirmed, and, on the basis of the aforementioned
associations of PADI4 genotype with clinical RA characteristics,
possible explanations for the heterogeneity of previous associa-
tion studies assessing PADI4 in RA may be delineated.
In this study, we tested the hypothesis that PADI4 genotype
influences the clinical course of RA directly or dependent on the
presence of anti-CCPs. As our study population consisted
predominantly of patients with established disease, we primar-
ily used CTI as a marker of disease severity as previously
suggested.13 CTI represents one major confounder of the erosive
joint status itself, as the therapeutic intensity significantly
influences joint destruction.20 The strong and highly significant
association of erosive disease with CTI in univariate and
multivariate analyses corroborates the validity of CTI as an
indicator of disease severity. Moreover, a highly significant
negative association between CTI and DAS28 was observed
(table 2). This association is in line with previous reports
Figure 2 Influence of padi4_94C.T on erosive joint status.
Frequencies of carriers of (A) one padi4_94T copy (padi4_94T) and (B)
two padi4_94T copies (padi4_94T/T) in controls and patients with RA
ordinally categorised by Steinbrocker score ( I, II, III, IV) are shown. For
analyses based on Steinbrocker score (I as reference group p values
after adjustment for sex, age, duration of disease, disease activity score
28, cumulative therapy intensity and serological status are given.
Figure 3 Presence of antinuclear antibodies (ANAs) is interactively
dependent on padi4_94C.T genotype and shared epitope. Frequencies
of ANA-positive (titre >320) patients with RA in dependency on
padi4_94C.T genotype and presence (SE) or absence (se/se) of shared
epitope are given. There was significant (p = 0.001) heterogeneity
between the two strata with respect to the relation between
padi4_94C.T and ANA positivity.
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describing significantly more pronounced DAS reductions with
more intensive treatment strategies.21 22 DAS28 reflects current
disease activity and the underlying disease biology, but it is also
influenced by the therapeutic approaches. The fact that CTI is
associated with erosive disease and related to DAS28 under-
scores the value of this disease activity tool. Considering our
primary hypothesis, we revealed a strong modulating effect of
padi4_94C.T genotype on the anti-CCP-mediated influence on
CTI (table 2). The association of anti-CCPs with CTI was
restricted to carriers of padi4_94T. From a different perspective,
in anti-CCP-negative patients, there was no significant associa-
tion of padi4_94C.T genotype with CTI (fig 1B), but, in anti-
CCP-positive patients, the proportion of padi4_94T carriers
increased progressively with increasing CTI categories (trend
test, p = 0.004) (fig 1A). When this phenomenon was analysed
in relation to padi4_94T copy number, there was an increase in
anti-CCP-positive patients with high therapy intensity (CTI-2/3)
from 53.5% for padi4_94C/C (wild-type) to 65.1% and 81.3%
for the presence of one and two padi4_94T alleles, respectively
(trend test, p,0.003) (data not shown). The categorisation of
CTI, which we defined a priori as a local adaptation of the one
described previously, is of course arbitrary. Moreover, this
measure of disease severity is difficult to standardise. However,
post hoc analyses based on CTI categories, which exactly reflect
those previously described, did not substantially alter the
results.13 A modulating effect of padi4_94C.T genotype on
anti-CCP-mediated severity of disease can be explained in
several ways. The stability of mRNA derived from PADI4
susceptibility genotypes is increased, and high concentrations of
PADI4 in inflamed synovium are specific to patients with
RA.12 23 Thus, an increased amount of intra-articular immune
complexes may increase disease severity in anti-CCP-positive
carriers of padi4_94T. Differences in responsiveness to anti-
rheumatic drugs may be another explanation for this finding.
The second major finding of this study is the significant trend
towards higher padi4_94T carrier frequency with increasing
Steinbrocker score (fig 2), although padi4_94C.T itself was not
associated with erosive disease defined as Steinbrocker score
>II. Thus, PADI4 genotype was associated with more intense
joint destruction corresponding to Steinbrocker scores III and
IV. Interestingly, the padi4_94T carrier frequencies of patients
with RA with the lowest CTI (CTI-1, 63.0%) or non-erosive
disease (Steinbrocker score (I, 67.6%) are nearly exactly the
same as in our controls (61.9%) (figs 1 and 2). This finding
may help us to understand discrepant results from different
association studies performed on PADI4 genotype and
susceptibility to RA10 11 because the disease severity of the
study population appears to influence significantly the
padi4_94C.T genotype distribution. In the present study,
padi4_94T carrier status and padi4_94T allele dose were
significantly associated with susceptibility to RA when a
case–control analysis was performed (OR = 1.38, p = 0.02 and
trend test, p = 0.005, respectively). This association of
padi4_94T with RA was restricted to patients with higher
CTI (CTI-2/3) or erosive disease (Steinbrocker score >II).
Thus, study populations from tertiary care units consisting of
patients with RA with longstanding disease and long
therapeutic histories could be positively selected for so-called
susceptibility genotypes of PADI4.
Anti-CCP presence is a well-established risk factor for erosive
disease.24 25 The lack of association of anti-CCP presence with
erosive disease in our study population needs consideration. The
predictive value of anti-CCPs with respect to joint destruction
seems to depend on the treatment strategy, as, in a recent
study, progressive disease could only be predicted by anti-CCPs
in those patients treated with sequential monotherapy.26 As a
step-up combination therapy approach was predominantly
chosen in our patients, the effect of anti-CCPs on joint
destruction may have been attenuated. The current data
mandate a prospective study, which should not only address
the genetic and serological profile but also take advantage of
more sensitive methods for evaluating radiological changes.
Finally, the interactive influence of padi4_94C.T and SE on
ANAs should be addressed (table 3). The highly heterogeneous
association of padi4_94C.T genotype with ANAs between the
two SE strata is an unexpected finding. However, as this
phenomenon was found for padi4_94T carrier status as well as
in a marked padi4_94C.T allele-dose-dependent fashion, this
finding appears to be conclusive. However, despite the high level
of significance for the testing for heterogeneity between the two
SE strata, further studies should be carried out to confirm this
finding. It could be argued that SE contributes to susceptibility
to RA primarily by mediating anti-CCP generation, and that, in
SE-negative RA, alternative pathogenetic pathways are
involved, which may be promoted by padi4_94T possibly by
generating autoantibodies predominantly reactive with nuclear
antigens.
Several limitations of our study should be discussed. The
main findings are based on retrospective case-only analyses.
Thus, biases due to the selection of an appropriate control group
can be excluded.27 Nevertheless, confounding due to possible
selective referral of patients has to be kept in mind. The size of
Table 3 Interactive influence of shared epitope and padi4_94C.T genotype on presence of antinuclear
antibodies
Shared epitope padi4_94C.T OR (p value) p* Adjusted OR (p value) p*
se/se C/C 1.0 (referent)
3.52 (0.05)
,0.01 1.0 (referent)
6.20 (,0.04)
0.006
se/se T
SE C/C 1.0 (referent)
0.49 (0.07)
1.0 (referent)
0.36 (,0.02)SE T
se/se C/C 1.0 (referent) 0.001 1.0 (referent) 0.0002
se/se C/T 2.83 (0.14) 4.71 (0.09)
se/se T/T 5.15 (,0.03) 9.58 (,0.02)
SE C/C 1.0 (referent) 1.0 (referent)
SE C/T 0.62 (0.25) 0.50 (0.13)
SE T/T 0.27 (,0.02) 0.16 (0.004)
Odds ratios (ORs) and p values of univariate and multivariate analyses (adjusted for sex, antibody to cyclic citrullinated peptide,
rheumatoid factor, disease duration, disease activity score 28, cumulative therapy intensity) are given. se/se, shared epitope
negative; SE, shared epitope positive.
*p values for test of homogeneity across SE strata.
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the study population does not allow a detailed sub-stratifica-
tion, which would help us to completely understand the
interactive effects of SE and padi4_94C.T on autoantibody
profile and the conjoint influence of all three variables on
clinical course of RA. Moreover, data on environmental RA risk
factors in our study population are missing, which may have
helped to elucidate gene–environment interactions.
Nevertheless, the data presented suggest that combined
information on PADI4 genotype and anti-CCP status may
represent key data for defining signatures of RA subsets with
different clinical courses. Moreover, the interactive influence of
PADI4 genotype and SE on the generation of differentiated
autoantibody profiles may provide further evidence for the
existence of different pathogenetic pathways in RA.
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